Srdan Verstovsek

Has grant

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML

Open Date: 2020-04-01

Close Date: 2025-03-01

Grant: Close

Myeloproliferative Neoplasms

Open Date: 2020-01-01

Close Date: 2021-01-01

Grant: Close

Research Support for Myeloproliferative Neoplasms

Open Date: 2019-02-01

Close Date: 2022-02-01

Grant: Close

Myeloproliferative Neoplasms

Open Date: 2019-01-01

Close Date: 2019-01-01

Grant: Close

Myeloproliferative Neoplasms

Open Date: 2018-01-01

Close Date:

Articles (23)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

Vikas Gupta

CANADA

View details

Stephen T. Oh

UNITED STATES

View details

Donal P. McLornan

UNITED KINGDOM

View details

Valerio De Stefano

ITALY

View details

Rashmi Kanagal Shamanna

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jean-Jacques Kiladjian

FRANCE

View details

Aaron Gerds

Assitant Professor

Cleveland Clinic

UNITED STATES

View details

Tareq Abuasab

Assistant Professor

Baylor College of Medicine

UNITED STATES

View details

PRITHVIRAJ BOSE

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ivan Krecak

CROATIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Srdan Verstovsek

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (23)

Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Interferons in the treatment of myeloproliferative neoplasms.

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.

Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.

Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments

Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis

Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.

Clinical development and management of adverse events associated with FGFR inhibitors.

Collaborators (10)

Vikas Gupta

Stephen T. Oh

Donal P. McLornan

Valerio De Stefano

Rashmi Kanagal Shamanna

Jean-Jacques Kiladjian

Aaron Gerds

Tareq Abuasab

PRITHVIRAJ BOSE

Ivan Krecak

Make your next move.